The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
On Tuesday 4th June an oral abstract session took place at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. During that session, Abstract 7508 was presented by Jason Westin, MD Anderson Cancer Center, Houston, TX, USA, on the Smart Start clinical trial.1
Patients with diffuse large B-cell lymphoma (DLBCL) of the non-germinal center (non-GCB) molecular subtype exhibit an inferior outcome following standard chemotherapy, with < 50% being cured by R-CHOP.2 This phase II study (NCT02636322) investigated the efficacy of rituximab, lenalidomide, and ibrutinib (RLI) combination prior to standard chemotherapy treatment, in patients with newly-diagnosed non-GCB DLBCL.
The primary objective of this open-label, single-arm, investigator-initiated trial was overall response rate (ORR) after two RLI cycles and complete response (CR) rate following two cycles RLI plus six cycles of RLI in combination with standard chemotherapy.
Baseline characteristic
Total cohort (N = 60)
Median age (range)
63.5 (29–83)
Male patients
50%
International Prognostic index (IPI) score:
Median
0–1
2
3–5
3
16.7%
31.7%
51.7%
Disease stage III–IV
65%
Double expressor (Myc, Bcl2 positive by IHC)
54%
Double hit (Myc, Bcl6 positive by FISH)
2.7%
Ki-67:
>80%
>90%
77%
49%
RLI only
(cycles 1–2;
n= 58)
RLI + 2 chemotherapy cycles
(cycles 1–4;
n= 56)
End of treatment (cycles 1–8;
n= 49)
ORR
86%
100%
100%
CR
36%
73%
96%
Partial response (PR)
50%
27%
4%
Stable disease (SD)
7%
-
-
Progressive disease (PD)
2%
-
-
Missing response (MR)
5%
-
-
References